The Liver Meeting 2025

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.